The American Cancer Society has issued its first updated prostate cancer screening guideline since 2010, recommending regular PSA blood testing beginning at age 50 for men at average risk—and earlier, more frequent testing for men at higher risk.
Released November 12, the recommendations mark a shift from the organization’s previous emphasis on discussing whether to undergo screening. ACS now directly recommends regular testing, while continuing to stress that patients should understand its benefits, limitations and possible harms before beginning.
The change reflects stronger evidence that screening reduces deaths and diagnoses of advanced prostate cancer, along with improved ways to avoid unnecessary biopsies and treatment. ACS estimates that 333,830 men will be diagnosed with prostate cancer in the United States in 2026 and 36,320 will die from the disease.
Who should be screened—and when?
The recommended schedule depends on age and risk:
Men with inherited genetic risks, including certain BRCA2 mutations, should discuss an appropriate screening schedule with their healthcare provider.
What about men over 70?
For men ages 70 through 74, ACS recommends an individual decision based on overall health, preferences and the uncertain balance between screening’s benefits and harms. Those who continue should generally be screened every two years.
Routine screening is not recommended beginning at age 75. However, selected very healthy men ages 75 through 79, particularly those whose PSA levels have been rising, may discuss continued testing with their clinician. ACS discourages screening at age 80 and older, and at any age when life expectancy is less than 10 years.
An elevated PSA begins a follow-up process
The PSA test measures prostate-specific antigen in the blood. Under the updated guideline, an abnormal result should generally be repeated—preferably within two weeks to three months—before further evaluation.
The guideline uses a PSA threshold of 3.0 ng/mL for men ages 45 through 69 and 6.5 ng/mL for men ages 70 through 74. Most men whose elevated result is confirmed should be offered a prostate MRI and/or a validated biomarker test to help determine whether a biopsy is needed.
An elevated PSA does not establish a cancer diagnosis or automatically require a biopsy. Follow-up testing can help reduce unnecessary procedures, although some men with a high suspicion of cancer may be advised to proceed directly to biopsy.
Finding cancer does not always mean immediate treatment
For men diagnosed with low-risk prostate cancer, ACS recommends offering active surveillance as the initial management approach. This means structured monitoring, with treatment considered if the cancer shows signs of becoming more dangerous.
The recommendations also advise against using a digital rectal examination as the primary screening test.
The goal is to find potentially life-threatening cancers early while reducing the harm caused by diagnosing and treating cancers unlikely to threaten a man’s life. The guidance concerns screening; it does not replace the care plan for someone already diagnosed with prostate cancer.
Read the American Cancer Society’s updated patient guidance.
The post First Updated Prostate Cancer Screening Guidelines in 16 Years – American Cancer Society appeared first on RINewsToday.